- authorisedTherapeutic exploratory (Phase II)
An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up
This study is for people with Thyroid Eye Disease who previously took part in a trial for the drug AMG 732 but didn't see enough improvement in their bulging eyes or whose condition returned. It aims to see if continued treatment with AMG 732 can help further.
Spain · Poland - active not recruitingPHASE3
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
This study is testing a new medicine, teprotumumab, for people with active Thyroid Eye Disease (TED). We want to see if it can help reduce bulging eyes (proptosis) compared to a dummy medicine (placebo). It involves adults aged 18-80.
United States · Argentina · Australia - ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab
This study is looking at a new treatment called teprotumumab for Thyroid Eye Disease. It aims to safely see if different lengths of taking the medicine affect how well it works and if people need further treatment later.
France · Italy · Germany - active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
This study is testing a new medicine called satralizumab for people with Thyroid Eye Disease (TED). Researchers want to see if it's safe and effective, and how it works in the body to help improve the condition.
United States · Canada · China - ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, controlled, safety and tolerability study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with thyroid eye disease (TED)
This study is testing a new medicine, VRDN-001, for people with thyroid eye disease. It’s looking at how safe the medicine is and if it causes any side effects over 15 weeks.
Germany · Netherlands · Poland - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients with Thyroid Eye Disease
This study is testing a new medicine called LASN01 for people with an eye condition called Thyroid Eye Disease. Researchers want to see if LASN01 can help improve eye bulging and if it's safe to use. It's a key step to understand if this new treatment could work.
Spain · Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal studies
This study is for people with Thyroid Eye Disease whose previous treatment didn't work completely. It's testing a new medicine (VRDN-001) to see if it can reduce bulging eyes and improve other symptoms, aiming to find better ways to help those still struggling.
Czechia · Italy · Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
This study is testing a new medicine, Batoclimab, for people with an eye condition called Thyroid Eye Disease (TED). We want to see if this medicine can help reduce bulging eyes and improve other eye symptoms compared to a dummy medicine.
Slovakia · Spain · Hungary - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
This study is looking at a new medicine called linsitinib for people with a condition called Thyroid Eye Disease (TED). It wants to see how well it works and if it's safe. It's a follow-up to an earlier study, checking if the medicine helps reduce bulging eyes over time.
Spain · Italy - active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
This study is looking at a new medicine called satralizumab for people with Thyroid Eye Disease (TED). We want to see if it works well, if it's safe, and how it affects the body.
United States · Argentina · Australia - active not recruitingPHASE2, PHASE3
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
This study is testing a new medicine, linsitinib, for people with active, moderate to severe Thyroid Eye Disease (TED). Researchers want to see if it's safe and effective compared to a dummy pill over 24 weeks.
United States · Canada · Italy - recruiting
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
This study looks at how your body handles prednisolone, a common anti-inflammatory medicine, especially at higher doses. We're trying to understand if prednisolone levels in your blood are consistent and if they change over time, which could help tailor treatment for conditions like asthma or thyroid eye disease.
United Kingdom - ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-masked, placebo-controlled safety, tolerability, and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in participants with chronic thyroid eye disease (TED)
This study is testing a new medicine, VRDN-001, for people with an eye condition called Thyroid Eye Disease (TED). Researchers want to see if it's safe, if it helps improve eye bulging and other symptoms, and how well people tolerate it.
Spain · Hungary · Poland